3 November 2023 in The Breast
Almost two percent of individuals in the United States identify as gender non-conforming. In the female-to-male (FTM) transgender population, masculinizing hormone therapy with testosterone is commonly prescribed in gender transition. To date, the effects of exogenous androgens on breast tissue and its roles in altering breast cancer risk are poorly understood. This study examines the histopathologic findings in gender affirming mastectomy (GAM) in transgender FTM patients and the effects of exogenous androgens on estrogen receptors (ER) and androgen receptors (AR). A retrospective review of pathology specimens obtained between 2017 and 2020 was performed comparing androgen exposed breast tissue with breast tissue without androgen exposure. Breast specimens were obtained from patients who underwent FTM GAM with recorded exogenous androgen exposure. Control breast specimens were obtained from reduction mammoplasty (RM) procedures in cisgender women which were aged matched to the GAM cohort, as well as postmenopausal women with benign/prophylactic mastectomy procedures; all controls were without androgen exposure. The histopathologic findings were assessed. Immunohistochemistry for AR and ER was performed and the score interpreted by digital image analysis. Androgen-exposed breast tissue revealed dense fibrotic stroma, lobular atrophy, thickened lobular basement membranes, and gynecomastoid changes. Longer duration of androgen exposure resulted in a more pronounced effect. The incidence of atypia or cancer was lower in GAM than RM cohort. ER and AR expression was highest in transgender male breast tissue with intermediate duration of exogenous androgen exposure. Increased androgen exposure is associated with lobular atrophy and gynecomastoid changes in breast parenchyma. Overall, ER and AR are expressed strongly in lobular epithelium in patients with prolonged androgen exposure. Exogenous testosterone does not appear to increase risk for breast cancer. Additional studies are needed to investigate the mechanism responsible for these changes at a cellular level and its role in cancer development.
24 April 2020 in Journal of Surgical Research
5 November 2025 in Annals of Surgical Oncology
10 October 2026 in European Journal of Surgical Oncology
Pleomorphic lobular carcinoma in situ (PLCIS), a more aggressive variant of classic LCIS (CLCIS), demonstrates higher rates of upgrade to invasive carcinoma at surgical excision. Mammography may underestimate disease extent, whereas MRI may delineate lesions due to sensitivity. Our institutional pathology database was queried for patients diagnosed with PLCIS on core needle biopsy (CNB) from 2002 to 2025 who underwent surgical excision. Preoperative MRI and MRI-guided biopsies were reviewed. Radiologic, pathologic, surgical, and outcome data were collected. Proportions were summarized with 95% confidence intervals. Fisher's exact test assessed associations between categorical variables, and Bayesian logistic regression evaluated the relationship between calcification size and malignant upgrade. Preoperative MRI was performed in 94.7% (18/19) of patients. Among these, 61.1% (11/18) underwent additional biopsy, identifying additional LCIS in 72.7% (8/11), benign findings in 18.2% (2/11), and malignancy in 9.1% (1/11). Mammographic PLCIS presentation included calcifications (26.3%), mass (5.3%), both (31.6%), or neither (36.8%). Among cases with calcifications, 45.5% (5/11) upgraded to malignancy. Increasing calcification size was associated with higher upgrade probability (OR 1.32 per cm, 95% CrI: 0.68-2.97), increasing from 35% at 0.5 cm to 52% at 3.0 cm. The overall upgrade rate was 47.4% (9/19). Preoperative MRI in PLCIS frequently prompts additional biopsies, often detecting further LCIS rather than malignancy. Calcification extent predicts upgrade, and the high upgrade rate supports surgical excision after CNB diagnosis.